Antimicrobials for bacterial bioterrorism agents

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Meselson M, Guillemin J, Hugh-Jones M et al.: The Sverdolovsk anthrax outbreak of 1979. Science266,1202–1208 (1994).
  Medline CASGoogle Scholar
• 2  Inglesby T, Dennis D, Henderson D et al.: Plague as a biological weapon. J. Am. Med. Assoc.23,2281–2290 (2000).
  Google Scholar
• 3  Mohammed M, Marston C, Popovic T, Weyant R, Tenover F: Antimicrobial susceptibility of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and E-test agar gradient diffusion methods. J. Clin. Microbiol.40,1902–1907 (2002).
  Medline CASGoogle Scholar
• 4  Steward J, Lever MS, Simpson AJH, Sefton AM, Brooks TJG: Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. J. Antimicrob. Chemother.54,95–99 (2004).
  Medline CASGoogle Scholar
• 5  Heine HS, Bassett J, Miller L et al.: Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob. Agents Chemother.51,1373–1379 (2007).
  Medline CASGoogle Scholar
• 6  Peterson JW, Moen ST, Healy D et al.: Protection afforded by fluoroquinolones in animal models of respiratory infections with Bacillus anthracis, Yersinia pestis and Francisella tularensis. Open Microbiol.4,34–46 (2010).
  Medline CASGoogle Scholar
• 7  Friedlander AM, Welkos SL, Pitt ML et al.: Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis.167,1239–1243 (1993).
  Medline CASGoogle Scholar
• 8  Deziel MR, Heine HA, Louie M et al.: Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother.49,5099–5106 (2005).
  Medline CASGoogle Scholar
• 9  Kao M, Bush K, Barnewall R et al.: Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob. Agents Chemother.50,3535–3542 (2006).
  Medline CASGoogle Scholar
• 10  Oyston PC: Francisella tularensis: unravelling the secrets of an intracellular pathogen. J. Med. Microbiol.57,921–930 (2008).
  MedlineGoogle Scholar
• 11  Dennis D, Inglesby T, Henderson D et al.: Tularemia as a biological weapon. J. Am. Med. Assoc.285,2763–2773 (2001).
  Medline CASGoogle Scholar
• 12  Russell P, Eley SM, Fulop MJ, Bell DL, Titball RW: The efficacy of ciprofloxacin and doxycycline against experimental tularemia. J. Antimicrob. Chemother.41,461–465 (1998).
  Medline CASGoogle Scholar
• 13  Chocarro A, Gonzalez A, Garcia I: Treatment of tularemia with ciprofloxacin. Clin. Infect. Dis.31,623 (2000).
  Medline CASGoogle Scholar
• 14  Limaye A, Hooper C: Treatment of tularemia with fluoroquinolones: two cases and a review. Clin. Infect. Dis.29,922–924 (1999).
  Medline CASGoogle Scholar
• 15  Pérez-Castrillión J, Bachiller-Lurque P, Martín-Luquero M, Mena-Martin F, Herreros V: Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin. Infect. Dis.33,573–576 (2001).
  MedlineGoogle Scholar
• 16  Johansson A, Berglund L, Gothefors L, Sjöstedt A, Tärnvik A: Ciprofloxacin for treatment of tularemia in children. Paediatr. Infect. Dis. J.19,449–453 (2000).
  Medline CASGoogle Scholar
• 17  Johansson A, Berglund L, Gothefors L, Sjöstedt A, Tärnvik A: Ciprofloxacin for treatment of tularemia. Clin. Infect. Dis.33,267–268 (2001).
  Medline CASGoogle Scholar
• 18  Nelson M, Lever MS, Dean RE, Pearce PC, Stevens DJ, Simpson AJ: Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus). Antimicrob. Agents Chemother.54,3922–3926 (2010).
  Medline CASGoogle Scholar
• 19  Inglesby TV, Dennis DT, Henderson DA et al.: Plague as a biological weapon: Medical and public health management. J. Am. Med. Assoc.283,2281–2290 (2000).
  CASGoogle Scholar
• 20  Wong J, Barash J, Sandfort R, Janda J: Susceptibilities of Yersinia pestis strains to 12 antimicrobial agents. Antimicrob. Agents Chemother.44,1995–1996 (2000).
  Medline CASGoogle Scholar
• 21  Smith M, Vinh D, Hoa N, Wain J, Thung D, White N: In vitro antimicrobial susceptibilities of strains of Yersinia pestis. Antimicrob. Agents Chemother.39,2153–2154 (1995).
  Medline CASGoogle Scholar
• 22  Russell P, Eley SM, Green M et al.: Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. J. Antimicrob. Chemother.41,301–305 (1998).
  Medline CASGoogle Scholar
• 23  Byrne W, Welkos S, Pitt M et al.: Antibiotic treatment of experimental pneumonic plague in mice. Antimicrob. Agents Chemother.42,675–681 (1998).
  Medline CASGoogle Scholar
• 24  Galimand M, Guiyoule A, Gerbaud G et al.: Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N. Engl. J. Med.337,677–680 (1997).
  Medline CASGoogle Scholar
• 25  Goiyoule A, Gerbaud G, Buchrieser C et al.: Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg. Infect. Dis.7,43–48 (2001).
  MedlineGoogle Scholar
• 26  Currie BJ, Fisher DB, Anstey NM, Jacups SP: Melioidosis: acute and chronic disease, relapse and re-activation. Trans. R. Soc. Trop. Med. Hyg.94,301–304 (2000).
  Medline CASGoogle Scholar
• 27  Ngauy V, Lemeshev Y, Sadkowski L, Crawford G: Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J. Clin. Microbiol.43,970–972 (2005).
  MedlineGoogle Scholar
• 28  Wagg DM, DeShazer D: Glanders, new insights into an old disease. In: Biological Weapons Defense: Infectious Diseases and Counterterrorism. Lindler LE, Lebeda FJ, Korch GW (Eds). Humana Press, Inc., Totowa, NJ, USA, 209–238 (2004).
  Google Scholar
• 29  Hawley RJ, Eitzen EM: Biological weapons – a primer for microbiologists. Ann. Rev. Microbiol.55,235–253 (2001).
  Medline CASGoogle Scholar
• 30  White NJ: Melioidosis. Lancet361,1715–1722 (2003).
  Medline CASGoogle Scholar
• 31  Heptonstall J, Gent N: CRBN Incidents: Clinical Management & Health Protection. Health Protection Agency, London, UK (2008).
  Google Scholar
• 32  Russell P, Eley SM, Ellis J et al.: Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J. Antimicrob. Chemother.45,813–818 (2000).
  Medline CASGoogle Scholar
• 33  Sivalingam SP, Sim SH, Jasper LC, Wang D, Liu Y, Ooi EE: Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole. J. Antimicrob. Chemother.61,674–678 (2008).
  Medline CASGoogle Scholar
• 34  Bertino J Jr, Fish D: The safety profile of the fluoroquinolones. Clin. Ther.22,798–817 (2000).
  Medline CASGoogle Scholar
• 35  Brouillard JE, Terriff CM, Tofan A, Garrison MW: Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents. Pharmacotherapy26,3–14 (2006).▪ Highlights the issues surrounding currently available antibiotics that are effective against most bioterrorism agents.
  Medline CASGoogle Scholar
• 36  Rotz LD, Khan AS, Lillibridge SR et al.: Public health assessment of potential biological terrorism agents. Emerg. Infect. Dis.8,225–230 (2002).
  MedlineGoogle Scholar
• 37  Galimand M, Carniel E, Courvalin P: Resistance of Yersinia pestis to antimicrobial agents. Antimicrob. Agents Chemother.50,3233–3236 (2006).
  Medline CASGoogle Scholar
• 38  Viktorov DV, Zakharova IB, Podshivalova MV et al.: High-level resistance to fluoroquinolones and cephalosporins in Burkholderia pseudomallei and closely related species. Trans. R. Soc. Trop. Med. Hyg.102,S103–S110 (2008).
  MedlineGoogle Scholar
• 39  Holden MT, Titball RW, Peacock SJ et al.: Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl Acad. Sci. USA101,14240–14245 (2004).
  Medline CASGoogle Scholar
• 40  Nierman WC, DeShazer D, Kim HS et al.: Structural flexibility in the Burkholderia mallei genome. Proc. Natl Acad. Sci. USA101,14246–14251 (2004).
  Medline CASGoogle Scholar
• 41  Larsson P, Oyston PC, Chain P et al.: The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nature Genet.37,153–159 (2005).
  Medline CASGoogle Scholar
• 42  Parkhill J, Wren BW, Thomson NR et al.: Genome sequence of Yersinia pestis, the causative agent of plague. Nature413,523–527 (2001).
  Medline CASGoogle Scholar
• 43  Read TD, Peterson SN, Tourasse N et al.: The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature423,81–86 (2003).
  Medline CASGoogle Scholar
• 44  Thomson N, Holden M, Parkhill J: Brothers in arms. Nature Rev. Microbiol.3,100–101 (2005).▪ Interesting article on genome comparison of some bioterrorism agents to their lesser pathogenic relations.
  Medline CASGoogle Scholar
• 45  Chain PS, Carniel E, Larimer FW et al.: Insights into the evolution of Yersinia pestis through whole-genome comparison with Yersinia pseudotuberculosis. Proc. Natl Acad. Sci. USA101,13826–13831 (2004).
  Medline CASGoogle Scholar
• 46  Zhang R, Lin Y: DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res.37,D455–D458 (2009).
  Medline CASGoogle Scholar
• 47  Zhang R, Ou HY, Zhang CT: DEG: a database of essential genes. Nucleic Acids Res.32,D271–D272 (2004).
  Medline CASGoogle Scholar
• 48  Duffield M, Cooper I, McAlister E et al.: Predicting conserved essential genes in bacteria: in silico identification of putative drug targets. Mol. Biosystems6,2482–2489 (2010).
  Medline CASGoogle Scholar
• 49  Cuccui J, Easton A, Chu KK et al.: Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis. Infect. Immun.75,1186–1195 (2007).
  Medline CASGoogle Scholar
• 50  Flashner Y, Mamroud E, Tidhar A et al.: Identification of genes involved in Yersinia pestis virulence by signature-tagged mutagenesis. Adv. Exp. Med. Biol.31–33 (2003).
  MedlineGoogle Scholar
• 51  Leigh SA, Forman S, Perry RD et al.: Unexpected results from the application of signature-tagged mutagenesis to identify Yersinia pestis genes required for adherence and invasion. Microb. Pathog.38,259–266 (2005).
  Medline CASGoogle Scholar
• 52  Su JL, Yang J, Zhao DM et al.: Genome-wide identification of Francisella tularensis virulence determinants. Infect. Immun.75,3089–3101 (2007).
  Medline CASGoogle Scholar
• 53  Atkins TP, Prior R, Mack K et al.: Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J. Med. Microbiol.51,539–547 (2002).
  Medline CASGoogle Scholar
• 54  DeShazer D, Brett P, Woods D: The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required from serum resistance and virulence. Mol. Microbiol.30,1081–1100 (1998).
  Medline CASGoogle Scholar
• 55  DeShazer D, Waag DM, Fritz DL et al.: Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridisation and demonstration that the encoded capsule is an essential virulence determinant. Microb. Pathog.30,253–269 (2001).
  Medline CASGoogle Scholar
• 56  Reckseidler S, DeShazer D, Sokol PA et al.: Detection of bacterial virulence genes by subtractive hybridisation: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect. Immun.69,34–44 (2001).
  Medline CASGoogle Scholar
• 57  Milne TS, Michell SL, Diaper H et al.: A 55 kDa hypothetical membrane protein is an iron-regulated virulence factor of Francisella tularensis subsp novicida U 112. J. Med. Microbiol.56,1268–1276 (2007).
  Medline CASGoogle Scholar
• 58  Dufva M, Christensen CBV: Diagnostic and analytical applications of protein microarrays. Expert Rev. Proteom.2,41–48 (2005).
  Medline CASGoogle Scholar
• 59  Felgner PL, Kayala MA, Vigil A et al.: A Burkholderia pseudomallei protein microarray reveals serodiagnostic nd cross-reactive antigens. Proc. Natl Acad. Sci. USA106,13499–13504 (2009).
  Medline CASGoogle Scholar
• 60  Frearson JA, Wyatt PG, Gilbert IH et al.: Target assessment for antiparasitic drug discovery. Trends Parasitol.23,589–595 (2007).▪ Relevant publication on antimicrobial target selection and prioritization.
  Medline CASGoogle Scholar
• 61  Galan JE, Wolf-Watz H: Protein delivery into eukaryotic cells by type III secretion machines. Nature444,567–573 (2006).
  Medline CASGoogle Scholar
• 62  Cornelis GR: The Yersinia YSC-YOP ‘type III’ weaponry. Nature Rev. Mol. Cell Biol.3,742–752 (2002).
  Medline CASGoogle Scholar
• 63  Aiello D, Williams JD, Majgier-Baranowska H et al.: Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III Secretion. Antimicrob. Agents Chemother.54,1988–1999 (2010).
  Medline CASGoogle Scholar
• 64  Felise HB, Nguyen HV, Pfuetzner RA et al.: An inhibitor of Gram-negative bacterial virulence protein secretion. Cell Host Microbe4,325–336 (2008).
  Medline CASGoogle Scholar
• 65  Kauppi AM, Nordfelth R, Uvell H et al.: Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol.10,241–249 (2003).
  Medline CASGoogle Scholar
• 66  Pan NJ, Brady MJ, Leong JM et al.: Targeting type III secretion in Yersinia pestis. Antimicrob. Agents Chemother.53,385–392 (2009).
  Medline CASGoogle Scholar
• 67  Cornelis GR, Boland A, Boyd AP et al.: The virulence plasmid of Yersinia, an antihost genome. Microbiol. Mol. Biol. Rev.4,1315 (1998).
  Google Scholar
• 68  Wren BW: The Yersiniae – a model genus to study the rapid evolution of bacterial pathogens. Nature Rev. Microbiol.1,55–64 (2003).
  Medline CASGoogle Scholar
• 69  Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M: Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun.73,3104–3114 (2005).
  Medline CASGoogle Scholar
• 70  Harmon DE, Davis AJ, Castillo C et al.: Identification and characterization of small-molecule inhibitors of YOP translocation in Yersinia pseudotuberculosis. Antimicrob. Agents Chemother.54,3241–3254 (2010).
  Medline CASGoogle Scholar
• 71  Sun GW, Gan YH: Unraveling type III secretion systems in the highly versatile Burkholderia pseudomallei. Trends Microbiol.18,561–568 (2010).
  Medline CASGoogle Scholar
• 72  Stevens M, Wood MW, Taylor LA et al.: An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol. Microbiol.46,649–659 (2002).
  Medline CASGoogle Scholar
• 73  Stevens MP, Friebel A, Taylor LA et al.: A Burkholderia pseudomallei type III secreted protein, BopE, facilitates bacterial invasion of epithelial cells and exhibits guanine nucleotide exchange factor activity. J. Bacteriol.185,4992–4996 (2003).
  Medline CASGoogle Scholar
• 74  Stevens MP, Haque A, Atkins T et al.: Attenuated virulence and protective efficacy of a Burkholderia pseudomallei BSA type III secretion mutant in murine models of melioidosis. Microbiology150,2669–2676 (2004).
  Medline CASGoogle Scholar
• 75  Erskine PT, Knight MJ, Ruaux A et al.: High resolution structure of BipD: an invasion protein associated with the type III secretion system of Burkholderia pseudomallei. J. Mol. Biol.363,125–136 (2006).
  Medline CASGoogle Scholar
• 76  Pal M, Erskine PT, Gill RS et al.: Near-atomic resolution analysis of BipD, a component of the type III secretion system of Burkholderia pseudomallei. Acta Cryst. Struct. Biol. Crystal Comm.66,990–993 (2010).
  Medline CASGoogle Scholar
• 77  Graumann PL: Cytoskeletal elements in bacteria. Ann. Rev. Microbiol.61,589–618 (2007).
  Medline CASGoogle Scholar
• 78  Margalit DN, Romberg L, Mets RB et al.: Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc. Natl Acad. Sci. USA101,11821–11826 (2004).
  Medline CASGoogle Scholar
• 79  Paradis-Bleau C, Sanschagrin F, Levesque RC: Peptide inhibitors of the essential cell division protein FtsA. Prot. Eng. Design Select.18,85–91 (2005).
  Medline CASGoogle Scholar
• 80  Stokes NR, Sievers J, Barker S et al.: Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J. Biol. Chem.280,39709–39715 (2005).
  Medline CASGoogle Scholar
• 81  Foss MH, Weibel DB: Oligochlorophens are potent inhibitors of Bacillus anthracis. Antimicrob. Agents Chemother.54,3988–3990 (2010).
  Medline CASGoogle Scholar
• 82  Paul SM, Mytelka DS, Dunwiddie CT et al.: How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Rev. Drug Discov.9,203–214 (2010).▪ Interesting review of the challenges faced by the biopharmaceutical industry in development of novel antimicrobials.
  Medline CASGoogle Scholar
• 83  Payne D: Approaches for tackling the challenges of antibacterial discovery. Presented at: Antibiotics 2001 – Where Now? London, UK, 20 January 2011.
  Google Scholar
• 101  Centers for Disease Control and Prevention: Bioterrorism agents/diseases www.bt.cdc.gov/agent/agentlist-category.asp
  Google Scholar
• 102  Health Protection Agency: Tularemia: guidelines for action in the event of a deliberate release, 6 November 2009 www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947357555
  Google Scholar